1198620-71-1

Upstream product

• 1198621-03-2 N,9-bis(benzyloxy)-3,3-dimethyl-1,5-dibydro-[1,3]dioxepino[5,6-c]pyridine-8-carboxamide 
• 1198621-04-3 N,3-bis(benzyloxy)-4,5-bis(hydroxymethyl)picolinamide 
• 1198621-05-4 N,7-bis(benzyloxy)-3-oxo-1,3-dihydrofuro[3,4-c]pyridine-6-carboxamide 
• 100-46-9 benzylamine 
• 1198621-19-0 5-carboxyl-2,2-dimethyl-4H-[1,3]dioxino[4,5-c]pyridine-8-carboxylic acid methyl ester 
• 1198621-67-8 5-formyl-2,2-dimethyl-4H-[1,3]dioxino[4,5-c]pyridine-8-carboxylic acid methyl ester 
• 1198621-68-9 methyl 5-(hydroxymethyl)-2,2-dimethyl-4H-[1,3]dioxino[4,5-c]pyridine-8-carboxylate 
• 1198621-38-3 C₂₉H₂₇N₃O₅ 

Relevant academic research and scientific papers

Pyridoxine hydroxamic acids as novel HIV-integrase inhibitors

A series of pyridoxine hydroxamic acid analog bearing a 5-aryl-spacers were synthesized. Evaluation of these novel HIV integrase complex inhibitors revealed compounds with high potency against wild-type HIV virus.

HIV INTEGRASE INHIBITORS FROM PYRIDOXINE

The present invention relates to pyridoxine (vitamin B6) derived compounds of formula (I), pharmaceutically acceptable salts, or solvates thereof, wherein R1, R2, R4, A, L B1 and B2 are as defined in the specification, and pharmaceutical compositions comprising the compounds. Compounds of formula (I) inhibit Human Immunodeficiency Virus (HΙV)-integrase enzyme and are useful for preventing and treating HIV infection and AIDS.